5210W-12: West Pfizer A7471042

CRC 11090: (ARCHER 1042 Study) A Phase 2, Multi-Cohort Study To Evaluate The Impact Of Prophylactic Intervention On Dermatologic And Gastrointestinal Adverse Events And Patient Reported Outcomes In Patients Treated With Dacomitinib (PF-00299804)

Type of Study
Cancer (Oncology) - Lung
Location
Swedish Cancer Institute
Short Description

Purpose: To assess the impact of prophylactic treatment on the incidence of adverse events in advanced refractory NSCLC patients treated with PF-00299804 daily as a single agent. To assess the impact of an interrupted PF-00299804 dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation (HER-1 mutation, HER-2 mutation or HER-2 amplification).

Status
Open to Enrollment
Principal Investigator
Howard (Jack) West, M.D.
Eligibility Notes
  • Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Prior systemic treatment which includes one standard chemotherapy and failed (refractory) for advanced or metastatic NSCLC
  • Evidence of disease but measurable disease is not mandatory
  • Eastern Cooperative Oncology Group (ECOG) Performance status 0-2, estimated creatinine clearance ≥15 mL/min
  • No prior treatment with an EGFR-targeted or HER-targeted agent.
  • No chemotherapy, radiotherapy, biological or investigational agents within 2 weeks of baseline disease assessments.
  • No patients with known diffuse interstitial lung disease
  • No inadequate liver function, including patients with severe liver impairment
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086